New insider activity at ProQR ( (PRQR) ) has taken place on July 21, 2026.

ProQR has drawn fresh insider confidence as Director Bart Filius snapped up 150,000 shares of the company’s stock in a recent transaction. The purchase, valued at $256,500, signals a meaningful personal investment by the director and may be seen by investors as a positive sign about ProQR’s prospects.

ProQR shares saw active trading as investors digested multiple capital-raising moves and fresh RNA-editing data. The stock faced dilution pressure from a registered direct offering and secondary sale by existing holders, even as a concurrent Eli Lilly private placement and standstill commitments signaled strategic support and balance-sheet strengthening.

Analysts trimmed price targets mainly to reflect the enlarged share count and the early-stage nature of AX-0810 Phase 1 biomarker results. While the Axiomer RNA editing data in healthy volunteers were viewed as validating target engagement and supportive for biliary atresia and other cholestatic indications, some cautioned that initial biomarker shifts may not yet prove disease-modifying, prompting more conservative valuation assumptions.